The pandemic revolutionized data collection and patient engagement in clinical trials.Although the life sciences industry has been historically cautious to adop 12 July 2022
Around one in 10 medical products in circulation in low- and middle-income countries is substandard or counterfeit, according to the World Health Organization ( 4 July 2022
One UK-based company is looking to transform the way metabolic disorders are treated, leveraging many of the same AI-based techniques used to great effect elsew 4 July 2022
Breakups can be messy, but 18 months after the UK formally left the European Union, the newly-empowered Medicines and Healthcare products Regulatory Agency (MHR 26 June 2022
Pharma can boast a major role in improving the quality of life of patients with diseases such as breast cancer and rheumatoid arthritis in Latin America, writes 17 June 2022
In the fifth of a series of Industry Leader pieces from biological reagent supplier and service provider Sino Biological, the company answers a series of questi 13 June 2022
Even as generic competition gathers, the treatment landscape in multiple myeloma will likely be dominated by Bristol Myers Squibb’s Revlimid (lenalidomide) for 7 June 2022
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news